Diagnosis of Incident Cancer After Cryptogenic Stroke: An Exploratory Analysis of the ARCADIA Randomized Trial

Babak B Navi¹, Cenai Zhang¹, Benjamin R Miller¹+15

• ¹From the Clinical and Translational Neuroscience Unit (B.B.N., C.Z., A.P., M.B., H.K.), Feil Family Brain and Mind Research Institute and Department of Neurology, Weill Cornell Medicine, New York; Department of Neurology (B.B.N.), Memorial Sloan Kettering Cancer Center, New York, NY; Department of Neurology (B.R.M., C.S.), University of Minnesota, Minneapolis; Division of Hematology and Oncology (M.C.), Department of Medicine, University of Vermont Larner College of Medicine, Burlington; Department of Neurology (S.E.K.), University of Pennsylvania School of Medicine, Philadelphia; Department of Neurology (D.T., W.L.), Department of Epidemiology (W.L.), and Department of Biostatistics (R.K.), University of Washington, Seattle; Department of Biostatistics (J.E.), Medical University of South Carolina, Charleston; Ochsner Neuroscience Institute (R.M.Z., J.T.), Ochsner Health, New Orleans, LA; Department of Neurology and Rehabilitation Medicine (J.P.B.), University of Cincinnati College of Medicine, OH; Sunnybrook Research Institute (D.J.G.), Hurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre, and Division of Neurology (D.J.G.), Department of Medicine, University of Toronto, Ontario, Canada; Department of Neurology (M.B.), Inselspital, Bern University Hospital and University of Bern, Switzerland; and Department of Neurology (M.S.V.E.), Vagelos College of Physicians and Surgeons, and Department of Epidemiology (M.S.V.E.), Mailman School of Public Health, Columbia University, New York, NY.